Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin with Liposomal-Annamycin
Final rept. 23 Sep 1996-30 Sep 2001
M D ANDERSON CANCER CENTER HOUSTON TX
Pagination or Media Count:
We studied the toxicity and antitumor activity of Liposomal-Annamycin in patients with metastatic breast carcinoma. Sixteen patients were treated. Toxicity was mild and consisted mostly of bone marrow suppression, particularly granulocytopenia. Non- hematological toxicity was less than what is usually seen with other anthracyclines. No responses were seen.
- Medicine and Medical Research